Jiangsu Aidea Pharmaceutical Co Ltd Tangible Net Worth Ratio
Jiangsu Aidea Pharmaceutical Co Ltd tangible net worth ratio. Jiangsu Aidea Pharmaceutical Co Ltd (688488) has a Tangible Net Worth Ratio of 78.9% as of June 2026. This metric is calculated by deducting intangible assets (CN¥205.67 Million) from net assets (CN¥974.37 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore Jiangsu Aidea Pharmaceutical Co Ltd (688488) equity growth momentum to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Jiangsu Aidea Pharmaceutical Co Ltd (2016–2025)
Tangible net worth ratio of Jiangsu Aidea Pharmaceutical Co Ltd from 2016 to 2025. This chart shows how Jiangsu Aidea Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 10 annual periods from 2016 to 2025. As of June 2026, the ratio stands at 78.9%, reflecting net assets of CN¥974.37 Million with intangible assets of CN¥205.67 Million CNY. Check 688488 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Jiangsu Aidea Pharmaceutical Co Ltd Tangible Net Worth Ratio by Year (2016–2025)
Jiangsu Aidea Pharmaceutical Co Ltd tangible net worth ratio by year from 2016 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for Jiangsu Aidea Pharmaceutical Co Ltd from 2016 to 2025, covering 10 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see market cap of Jiangsu Aidea Pharmaceutical Co Ltd.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 82.3% | CN¥1.07 Billion | CN¥190.18 Million | CN¥1.91 Billion | ▼ -0.8 pp |
| 2024 | 83.1% | CN¥1.07 Billion | CN¥180.41 Million | CN¥1.87 Billion | ▲ +1.2 pp |
| 2023 | 81.9% | CN¥1.13 Billion | CN¥203.72 Million | CN¥1.75 Billion | ▼ -3.0 pp |
| 2022 | 84.9% | CN¥1.20 Billion | CN¥181.07 Million | CN¥1.66 Billion | ▼ -2.5 pp |
| 2021 | 87.4% | CN¥1.31 Billion | CN¥165.14 Million | CN¥1.43 Billion | ▼ -1.9 pp |
| 2020 | 89.2% | CN¥1.36 Billion | CN¥146.21 Million | CN¥1.45 Billion | ▲ +12.6 pp |
| 2019 | 76.6% | CN¥556.24 Million | CN¥130.02 Million | CN¥780.98 Million | ▼ -3.4 pp |
| 2018 | 80.0% | CN¥522.71 Million | CN¥104.49 Million | CN¥708.95 Million | ▼ -4.7 pp |
| 2017 | 84.7% | CN¥514.09 Million | CN¥78.45 Million | CN¥659.24 Million | ▲ +9.7 pp |
| 2016 | 75.0% | CN¥300.40 Million | CN¥74.97 Million | CN¥443.55 Million | — |